Evelo Biosciences announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,576,111, entitled "Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097." The Evelo-owned patent covers the use of a proprietary Bifidobacterium strain for the treatment of cancer, including use in combination with anti-PD-1 antibodies and other checkpoint inhibitors, and is relevant to the Company’s ongoing Phase 1/2 clinical trial in oncology.

"The issuance of this patent reflects the strength of our platform and the capabilities of our scientists to identify microbial strains with compelling pharmacology," said Natalie Lissy, Senior Director of IP at Evelo. "We also are pursuing patent rights on this invention in multiple jurisdictions outside the United States which will further strengthen our IP portfolio."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.